brigatinib | Cancer Search

Details 3 Related Guidelines / Approvals

type

NCCN Guideline

nccn category

1

biomarker

biomarker

ALK Fusion

condition

condition

Non-Small Cell Lung Carcinoma

settings

settings

Advanced

settings

First line

settings

Metastatic

drugs

drug

brigatinib

drug types

drug

targeted therapy

references

link

Non-Small Cell Lung Cancer (NCCN Guidelines) [3.2022]

source

NCCN

brigatinib

biomarker

ALK Fusion

condition

Non-Small Cell Lung Carcinoma

disease state

Metastatic

drug

brigatinib

drug type

targeted therapy

brigatinib

biomarker

ALK Fusion

condition

Inflammatory Myofibroblastic Tumor

drug

brigatinib

drug type

targeted therapy

brigatinib

biomarker

ALK Fusion

condition

Non-Small Cell Lung Carcinoma

disease state

Advanced, +1 more state

therapeutic contexts

Subsequent line

drug

brigatinib

drug type

targeted therapy

3 therapies
Page 1 of 1